DK1246623T3 - Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf - Google Patents

Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf

Info

Publication number
DK1246623T3
DK1246623T3 DK00988011T DK00988011T DK1246623T3 DK 1246623 T3 DK1246623 T3 DK 1246623T3 DK 00988011 T DK00988011 T DK 00988011T DK 00988011 T DK00988011 T DK 00988011T DK 1246623 T3 DK1246623 T3 DK 1246623T3
Authority
DK
Denmark
Prior art keywords
adenosine
compounds
receptor
compounds specific
subject
Prior art date
Application number
DK00988011T
Other languages
Danish (da)
English (en)
Inventor
Arlindo L Castelhano
David J Witter
Bryan Mckibben
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/454,075 external-priority patent/US6686366B1/en
Priority claimed from US09/454,074 external-priority patent/US6878716B1/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Application granted granted Critical
Publication of DK1246623T3 publication Critical patent/DK1246623T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK00988011T 1999-12-02 2000-12-01 Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf DK1246623T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45425499A 1999-12-02 1999-12-02
US09/454,075 US6686366B1 (en) 1998-06-02 1999-12-02 Compounds specific to adenosine A3 receptor and uses thereof
US09/454,074 US6878716B1 (en) 1998-06-02 1999-12-02 Compounds specific to adenosine A1 receptor and uses thereof

Publications (1)

Publication Number Publication Date
DK1246623T3 true DK1246623T3 (da) 2006-11-13

Family

ID=27412585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00988011T DK1246623T3 (da) 1999-12-02 2000-12-01 Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf

Country Status (15)

Country Link
EP (2) EP1246623B1 (zh)
JP (1) JP2003519102A (zh)
KR (1) KR100840727B1 (zh)
AT (1) ATE335489T1 (zh)
AU (1) AU784878B2 (zh)
CA (1) CA2393179A1 (zh)
CY (1) CY1107653T1 (zh)
DE (1) DE60030002T2 (zh)
DK (1) DK1246623T3 (zh)
ES (1) ES2269217T3 (zh)
HK (1) HK1050319B (zh)
IL (2) IL149935A0 (zh)
MX (1) MXPA02005357A (zh)
PT (1) PT1246623E (zh)
WO (1) WO2001039777A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911612A (pt) 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
KR100897430B1 (ko) * 2000-12-01 2009-05-14 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ₁, ａ₂ａ 및 ａ₃ 수용체에 특이적인 화합물및 그의 용도
NZ525885A (en) * 2000-12-01 2005-01-28 Osi Pharm Inc Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
ATE528303T1 (de) 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
WO2003048120A2 (en) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
WO2003053361A2 (en) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
CA2479036A1 (en) 2002-03-13 2003-09-18 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
CA2520323C (en) * 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005004875A1 (ja) * 2003-07-14 2005-01-20 Sankyo Company, Limited 経肺投与用医薬組成物
JP5114627B2 (ja) 2006-03-27 2013-01-09 株式会社糖鎖工学研究所 トレハロース化合物および該化合物を含有する医薬
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
ATE535243T1 (de) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
WO2009052376A1 (en) 2007-10-18 2009-04-23 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
CA2873723A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
GB201711234D0 (en) 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
KR20240018000A (ko) * 2022-08-01 2024-02-13 주식회사 넥스트젠바이오사이언스 A3 아데노신 수용체 작용제로서의 신규한 퓨린 유도체 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910913A (en) * 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
PL175347B1 (pl) * 1992-04-03 1998-12-31 Upjohn Co Trójpierścieniowe heterocykliczne aminy aktywne farmaceutycznie
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5780450A (en) 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
JPH09291089A (ja) 1996-04-26 1997-11-11 Yamanouchi Pharmaceut Co Ltd 新規な５−チアゾリルウラシル誘導体又はその塩
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
JP2003517423A (ja) 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
BR9911612A (pt) * 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US9816053B2 (en) 2015-03-26 2017-11-14 Melynda S DelCotto Candle having a wooden wick with figured grain

Also Published As

Publication number Publication date
CA2393179A1 (en) 2001-06-07
HK1050319B (zh) 2007-04-04
EP1246623A4 (en) 2003-05-14
PT1246623E (pt) 2006-12-29
HK1050319A1 (en) 2003-06-20
ES2269217T3 (es) 2007-04-01
ATE335489T1 (de) 2006-09-15
AU2427001A (en) 2001-06-12
DE60030002T2 (de) 2007-03-08
KR20020064327A (ko) 2002-08-07
AU784878B2 (en) 2006-07-13
IL199869A0 (en) 2011-08-01
JP2003519102A (ja) 2003-06-17
DE60030002D1 (de) 2006-09-21
WO2001039777A8 (en) 2001-11-08
KR100840727B1 (ko) 2008-06-23
IL149935A0 (en) 2002-11-10
EP1246623A1 (en) 2002-10-09
EP1246623B1 (en) 2006-08-09
CY1107653T1 (el) 2013-04-18
EP1731520A1 (en) 2006-12-13
MXPA02005357A (es) 2003-05-19
WO2001039777A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
DK1246623T3 (da) Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
AP1893A (en) Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
NZ522326A (en) Adenosine A2A receptor antagonists
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
NO20053509D0 (no) Anvendelse av adenosin A2a -reseptomntagonister
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
HU229108B1 (en) Glucagon-like peptide-1 analogs
ZA909141B (en) Therapeutically active chloro substituted benzimidazoles,processes for their preparation as well as their use
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
HK1061817A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
BR0313665A (pt) Utilização de bupropion para o tratamento da sìndrome das pernas inquietas
BR9912008A (pt) Método de tratamento
BR0307479A (pt) Compostos orgânicos
BR0314647A (pt) Uso de derivados de 4-piridilmetil-ftalazina para a preparação de um medicamento para o tratamento de sìndromes melodisplásicas
IT1274012B (it) N-acetiltriptamine-2-sostituite, antagoniste ad elevata affinita' del recettore della melatonina
KR930004444U (ko) 피로회복을 위한 다목적 신체안마기
AU2002338309A1 (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
RU97105486A (ru) Цитомодулирующее средство для лечения острых респираторных заболеваний у детей раннего возраста